AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03399448
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a chemotherapy agent used for lymphodepletion prior to NYCE T cells.
Trial: NCT00140140
Drug: ABI-007
RxNorm normalized name: ABI-007 COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly intravenous infusions over 30 minutes.
Trial: NCT00140140
Drug: vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
Trial: NCT00140140
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.~Trastuzumab is commercially available and was not supplied by the Sponsor.
Trial: NCT01276704
Drug: secoisolariciresinol
RxNorm normalized name: Secoisolariciresinol
DrugBank: Secoisolariciresinol (DB12179)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg
Trial: NCT00654108
Drug: Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 milligrams(mg) will be administered orally twice daily for 5 days.
Trial: NCT02701673
Drug: Belinostat
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2.
Trial: NCT00203190
Drug: Topiramate
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02701673
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2.
Trial: NCT02701673
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.
Trial: NCT02701673
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan 60 mg/m2 by vein on Days -3 and -2.
Trial: NCT06278493
Drug: Gemzar
RxNorm normalized name: Gemzar
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: It is a chemotherapeutic drug.
Trial: NCT02684461
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.~Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles.
Trial: NCT02672995
Drug: bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent bevacizumab:~Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab.
Trial: NCT06446570
Drug: Durvalumab,Tremelimumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
Trial: NCT00319917
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT00320983
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan
Trial: NCT00320983
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin
Trial: NCT01829516
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin
Trial: NCT00380926
Drug: polyunsatturated fatty acids (fish oil)
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02862574
Drug: Andecaliximab
RxNorm normalized name: Andecaliximab
DrugBank: Andecaliximab (DB17564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered via subcutaneous injection once weekly
Trial: NCT02749747
Drug: Sulpiride use
RxNorm normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg sulpiride once a day use for 60 days
Trial: NCT04487444
Drug: Thymalfasin
RxNorm normalized name: Thymalfasin
DrugBank: Thymalfasin (DB04900)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic 28 amino acid peptide identical to naturally circulating compound
Trial: NCT03733327
Drug: Busulfan (BU)
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Busulfan was administered at 3.2 mg/kg/day on days-7 to -4.
Trial: NCT03733327
Drug: Etoposide (VP-16)
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide was administered at 15 mg/kg/day on days -3 to -2.
Trial: NCT01988077
Drug: Ipilimumab 5 MG/ML Injection [Yervoy]
RxNorm normalized name: ipilimumab 5 MG/ML Injection [Yervoy]
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2 treatments of Ipilimumab before transfer of TIL and 2 treatments of Ipilimumab after TIL
Trial: NCT02012517
Drug: Short antibiotic course (standard of care)
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
DrugBank: Ragweed pollen extract (DB05368)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03136055
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given Intravenously (IV)
Trial: NCT03136055
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT03136055
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT01421056
Drug: CHF 5074 1x
RxNorm normalized name: CHF-6333
DrugBank: CHF-6333 (DB17815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, 1x, once a day in the morning for 24 weeks
Trial: NCT01421056
Drug: CHF 5074 3x
RxNorm normalized name: CHF-6333
DrugBank: CHF-6333 (DB17815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 16 weeks
Trial: NCT03823989
Drug: Promitil
RxNorm normalized name: PROMITIL
DrugBank: JNJ-27548547 (DB15372)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first 6 patients recruited to the study will receive 1.25 mg/kg PROMITIL. If no dose-limiting toxicities (DLTs) are recorded by day 43 of the study, the second cohort of 6 patients will begin treatment at a dose level of 1.5 mg/kg PROMITIL. Upon completion of two treatment cycles, with ≤1 incident of DLTs in Cohort 2, a third cohort (n=6) will be recruited and will be treated with a dose level of 1.8 mg/kg.
Trial: NCT01822925
Drug: DA-9801 300mg
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg of DA-9801 in tablet form, 100 mg to be taken 3 times daily for 12 weeks.
Trial: NCT01822925
Drug: DA-9801 600mg
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of DA-9801 in tablet form, 200 mg to be taken 3 times daily for 12 weeks.
Trial: NCT01822925
Drug: DA-9801 900mg
RxNorm normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg of DA-9801 in tablet form, to be taken 300 mg to be taken 3 times daily for 12 weeks.
Trial: NCT00378092
Drug: Oral risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
Trial: NCT00378092
Drug: Risperidone Long-Acting Injection (RLAI)
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.
Trial: NCT00378092
Drug: Risperidone Long-Acting Injection (RLAI)
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
Trial: NCT01517984
Drug: Tacrolimus (CNI) Withdrawal
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.~Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal.
Trial: NCT00926614
Drug: pioglitazone (Actos)
RxNorm normalized name: pioglitazone Oral Tablet [Actos]
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pioglitazone 30 mg qd for 30 days, then increase to 45 mg
Trial: NCT00926614
Drug: atorvastatin (Lipitor)
RxNorm normalized name: atorvastatin Oral Tablet [Lipitor]
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: atorvastatin 40 mg for 30 days then increase to 80 mg daily
Trial: NCT02243358
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03070678
Drug: Sotagliflozin (SAR439954)
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT03808935
Drug: Medical Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental intervention will begin with two weeks of titration (100 mg to 200 mg of CBD per day), followed by four weeks of treatment (maximum 300 mg of CBD per day) and four weeks of maintenance (maximum 300 mg of CBD per day). A two week washout phase will slowly decrease the daily dose (200 mg to 100 mg of CBD per day). All daily doses are equally divided into a morning and evening dose.
Trial: NCT00132730
Drug: MK-0873 2.5 mg
DrugBank: MK-0873 (DB13029)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00968409
Drug: F18-FFNP
RxNorm normalized name: F18-FFNP
DrugBank: Fluorofuranylnorprogesterone F-18 (DB15282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of F18-FFNP
Trial: NCT01093131
Drug: Oral sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
Trial: NCT01093131
Drug: Intravenous sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
Trial: NCT04419246
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/kg intravenous tranexamic acid 10 minutes before the incision.
Trial: NCT01323608
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
Trial: NCT00906061
Drug: Gemcitabine and Docetaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
Trial: NCT00132730
Drug: MK-0873 1.25 mg
DrugBank: MK-0873 (DB13029)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00132730
Drug: MK-0873 0.75 mg
DrugBank: MK-0873 (DB13029)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04556253
Drug: AK104
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive AK104 by intravenous administration.
Trial: NCT00132730
Drug: Placebo to MK-0873
RxNorm normalized name: MK-0873
DrugBank: MK-0873 (DB13029)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03401320
Drug: Letrozole ISM
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2.5 mg Femara + single IM injection of 50-400 mg Letrozole ISM
Trial: NCT03373435
Drug: exendin 9-39
RxNorm normalized name: Exendin 4
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Exendin 9-39 is a competitive antagonist of GLP-1 at its receptor.
Trial: NCT02578082
Drug: TD-4208
RxNorm normalized name: triamcinolone diacetate Injectable Suspension [TDS Forte]
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A single inhaled dose of TD 4208 (175 mcg)
Trial: NCT01999192
Drug: Tregalizumab
RxNorm normalized name: Tregalizumab
DrugBank: Tregalizumab (DB13073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: humanized anti-CD4 mAb
Trial: NCT06563856
Drug: TEPEZZA
RxNorm normalized name: Tepezza
DrugBank: Teprotumumab (DB06343)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as a SubQ injection or IV injection.
Trial: NCT06563856
Drug: EDP
RxNorm normalized name: HEDP
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered as a SubQ injection.
Trial: NCT02219152
Drug: tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02219152
Drug: saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00718315
Drug: erlotinib [Tarceva]
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 150mg po daily
Trial: NCT00718315
Drug: fusidic acid [Verutex]
DrugBank: Fusidic acid (DB02703)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical, daily for 30 days.
Trial: NCT03825705
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A multi-target receptor tyrosine kinase inhibitor
Trial: NCT03132142
Drug: Capsaicin
RxNorm normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4x4 cm patch of 8% topical capsaicin applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
Trial: NCT03132142
Drug: Trans-cinnamaldehyde
RxNorm normalized name: trans-Cinnamaldehyde
DrugBank: Cinnamaldehyde (DB14184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1mL of 10% trans-cinnamaldehyde applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
Trial: NCT03132142
Drug: L-Menthol
RxNorm normalized name: L-menthol
DrugBank: Levomenthol (DB00825)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1mL of 40% L-menthol applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
Trial: NCT00399529
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms. The antibody decreases heterodimer formation with other members of the epidermal growth factor receptor (EGFR) family, thereby indirectly inhibiting signaling through the Ras/Raf/mitogen-activated protein kinases (MAPK) and Phosphatidylinositol 3-kinase(PI3K)/protein kinase B (Akt) pathways. It also inhibits tumor neovascularization, and augments apoptosis both in vitro and in vivo. Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.
Trial: NCT04466254
Drug: CPGJ602
RxNorm normalized name: CPGJ602
DrugBank: CPGJ602 (DB17485)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Q2W/QW iv
Trial: NCT04466254
Drug: cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: QW iv
Trial: NCT03109301
Drug: Selumetinib (AZD6244 hyd sulfate) 50mg/dose
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib will be administered at a starting dose of 50 mg/dose orally in patients 18 years or older; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
Trial: NCT03109301
Drug: Selumetinib (AZD6244 hyd sulfate) 25mg/m2
DrugBank: Selumetinib (DB11689)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Selumetinib will be administered at a starting dose of 25 mg/m2/dose in children \< 18 years of age; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
Trial: NCT03577743
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: -bevacizumab 15m.g/ kg + carboplatin 450m.g + paclitaxel 175m.g/m2 D1 /21 Day until disease progression or un acceptable toxicity .
Trial: NCT02985229
Drug: Mifepristone
RxNorm normalized name: Mifepristone
DrugBank: Mifepristone (DB00834)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The option of home or clinic administration of 200 mg oral mifepristone
Trial: NCT02985229
Drug: Misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 800 μg buccal misoprostol through 70 days LMP following administration of mifepristone
Trial: NCT00082355
Drug: Alteplase (Activase, Genentech)
RxNorm normalized name: Alteplase
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose of Alteplase will not exceed 10 mg/d/leg and is delivered in a concentration of 100ug/mL. The actual dose delivered is based upon the length of the thrombosed vein and 1 mL is injected directly into each centimeter of a thrombosed vein in a lower extremity. The treatment will be repeated up to 4 times over a 4 day period.
Trial: NCT00518479
Drug: Valsartan 160mg OD; Moxonidine 400mcg OD
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02007629
Drug: Riociguat (Adempas, BAY63-2521)
RxNorm normalized name: Riociguat
DrugBank: Riociguat (DB08931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riociguat / BAY63-2521 film-coated tablets will be used in this study at a dosage of either 0.5, 1.0, 1.5, 2.0, and 2.5 mg. 3 times daily
Trial: NCT02172014
Drug: midazolam and normal saline infusion
RxNorm normalized name: NS-2359
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
Trial: NCT02345239
Drug: Pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: proton pump inhibitor
Trial: NCT04435158
Drug: SHR-1222
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: water injection Route of administration: subcutaneous injection
Trial: NCT00454116
Drug: Vandetanib
RxNorm normalized name: Vandetanib
DrugBank: Vandetanib (DB05294)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: once daily oral tablet two doses
Trial: NCT00773292
Drug: ciclosporin
RxNorm normalized name: Ciclosporin
DrugBank: Cyclosporine (DB00091)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to trough ciclosporin concentration
Trial: NCT00093509
Drug: ifosfamide and mesna
RxNorm normalized name: ifosfamide / mesna
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 gm / m2 ifosfamide mixed in 1000 cc D5W infused continuously over 24 hours daily for 6 days (144 hours); total ifosfamide dose 12 gm/ m2. For the day infusion only MESNA (sodium 2-mercapto-ethanesulphonate) is mixed with ifosfamide as above and given at 2.5 gm / m2 / 24 hours.
Trial: NCT03906643
Drug: HS-201
RxNorm normalized name: Japan Yellow 201
DrugBank: Fluorescein (DB00693)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HS-201 will be administered intravenously as a single dose
Trial: NCT00413348
Drug: Lactobacillus acidophilus NCFM
RxNorm normalized name: Lactobacillus Acidophilus NCFM
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no